Received Mar 16, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA MNEXSPIKE)) | MODERNA | UNK | — | IM |
silent reflux; This spontaneous case was reported by a consumer and describes the occurrence of REFLUX LARYNGITIS (silent reflux) in a 73-year-old male patient who received mRNA-1273.251 (Spikevax LP.8.1 PFS) for COVID-19 prophylaxis. The suspect product included Pre-filled Syringe injection for COVID-19 prophylaxis. No Medical History information was reported. In October 2025, the patient received dose of mRNA-1273.251 (Spikevax LP.8.1 PFS) (Intramuscular use) 1 dosage form. On an unknown date, the patient started Pre-filled Syringe (unknown route) at an unspecified dose. On an unknown date, the patient experienced REFLUX LARYNGITIS (silent reflux). At the time of the report, REFLUX LARYNGITIS (silent reflux) outcome was unknown. No concomitant medication was reported. The event was described as a form of reflux disease. This condition involved stomach acids affecting the esophagus and nasal passages, leading to symptoms such as postnasal drip and coughing, without the typical heartburn associated with reflux. It was unknown if the patient experienced any additional symptoms/events. No treatment medication was reported. Most recent FOLLOW-UP information incorporated above includes: On 10-Mar-2026: Live non-significant follow-up received: references added.